Metabolic medicines

Acarbose

An intestinal carbohydrate-digestion inhibitor with evidence for delayed diabetes onset, but no cardiovascular-event benefit in ACE.

Randomized human prevention trials with differing clinical endpoints

Acarbose molecular structure — Structure reference · C25H43NO18

Practical use

Applying the explained evidence

Where it fits: An intestinal carbohydrate-digestion inhibitor with evidence for delayed diabetes onset, but no cardiovascular-event benefit in ACE.
Put the information into practice: Reducing a glucose excursion, delaying a diabetes diagnosis and preventing a heart attack are separate endpoints. Evidence for one does not establish the others.
The outcome being treated: Identify whether the evidence concerns a diagnosed condition, body weight, appetite or a laboratory marker. Check which outcomes were measured and over what follow-up before transferring a finding to another goal.
Keep this limit in view: The trial reduced diabetes incidence but not its main cardiovascular endpoint.

STOP-NIDDM: progression from impaired glucose tolerance

ACE: cardiovascular events versus diabetes diagnoses

Overview

Acarbose inhibits intestinal carbohydrate-digesting enzymes, slowing glucose delivery after meals. Its US indication is improving glycemic control in adults with type 2 diabetes alongside diet and exercise. Preventive trial findings are distinct from that approval.

Risks and limitations

Gas, diarrhea and abdominal discomfort are common. Cirrhosis, inflammatory bowel disease, obstruction and major digestive or absorption disorders are contraindications. Liver-enzyme elevations can occur. Added insulin or sulfonylureas can produce hypoglycemia even though acarbose alone usually does not.

How to read this

Reducing a glucose excursion, delaying a diabetes diagnosis and preventing a heart attack are separate endpoints. Evidence for one does not establish the others.

Research explained

STOP-NIDDM: progression from impaired glucose tolerance

Who was studied

1,429 people randomized; 1,368 included after exclusions for eligibility or missing postrandomization information. Follow-up averaged 3.3 years; diabetes was assessed with oral glucose tolerance testing.

Acarbose: diabetes during trial: 32 percent
Placebo: diabetes during trial: 42 percent

What was found

Diabetes developed in 32% with acarbose versus 42% with placebo (relative hazard 0.75; 95% CI 0.63 to 0.90). Early treatment discontinuation was 31% versus 19%.

What it cannot establish

Exclusions after randomization and unequal discontinuation complicate interpretation. Increased conversion during a three-month placebo period after treatment emphasizes delayed progression rather than a proven permanent cure.

Read the original study

ACE: cardiovascular events versus diabetes diagnoses

Who was studied

6,522 Chinese patients with coronary heart disease and impaired glucose tolerance, median follow-up five years; acarbose or placebo added to cardiovascular prevention treatment.

Acarbose: cardiovascular events: 14.4 percent
Placebo: cardiovascular events: 14.7 percent

What was found

The cardiovascular composite occurred in 470/3,272 versus 479/3,250 (HR 0.98; 95% CI 0.86 to 1.11). Diabetes developed in 436 versus 513 participants (rate ratio 0.82; 95% CI 0.71 to 0.94).

What it cannot establish

The primary cardiovascular result was negative despite fewer diabetes diagnoses. The population already had coronary disease; findings cannot establish longevity in healthy users.

Read the original study

A glucose benefit did not establish cardiac protection

ACE’s composite included cardiovascular death, heart attack, stroke, unstable-angina admission and heart-failure admission. It did not improve significantly.

Supporting source

Why digestive effects are expected

Carbohydrates that escape digestion reach the colon, where fermentation contributes to gas and discomfort. Existing bowel disease changes the risk assessment.

Supporting source

Hypoglycemia has a specific interaction

Acarbose delays sucrose breakdown. The label distinguishes glucose from table sugar when treating hypoglycemia in combination therapy; a clinician-established emergency plan matters.

Supporting source

Tolerability influences real-world value

STOP-NIDDM had more early discontinuation in the active arm. An intervention’s effectiveness depends partly on whether people can continue it.

Supporting source

Why older cardiovascular claims differ

An earlier STOP-NIDDM analysis reported fewer cardiovascular events, but only 47 participants had events, with a broad composite and 3.3-year average follow-up. Its signal and ACE’s later null primary result should both remain visible; different populations and endpoints limit direct comparison.

Supporting source